β3Gn-T8 Inhibitors

Chemical inhibitors of β3Gn-T8 can interfere with its function by disrupting the normal processing and maturation of glycoproteins, which are the substrates for this enzyme. Swainsonine, for instance, inhibits Golgi alpha-mannosidase II, an enzyme crucial in the N-linked glycan processing pathway. This inhibition leads to improper glycoprotein maturation, which in turn affects the availability of suitable substrates for β3Gn-T8, thereby inhibiting its function. Similarly, castanospermine and its prodrug celgosivir target glucosidases, blocking the removal of glucose residues necessary for the proper folding of N-linked glycoproteins. This misfolding results in glycoproteins that are not appropriately structured for further modification by β3Gn-T8. Kifunensine and 1-deoxymannojirimycin further contribute to this disruption by inhibiting mannosidase I and alpha-mannosidase respectively, leading to an accumulation of glycoproteins with incorrect glycan structures, which are not suitable substrates for β3Gn-T8.

Additionally, deoxynojirimycin and nojirimycin, both inhibitors of alpha- and beta-glucosidases, prevent the early stage glycoprotein folding and processing, resulting in a lack of properly folded glycoproteins for β3Gn-T8 to modify. Bromoconduritol, although it targets beta-glucuronidase, can still indirectly inhibit β3Gn-T8 by causing glycosylation imbalances that may affect the pool of glycoprotein substrates. Miglustat, with its inhibitory effects on glucosylceramide synthase and other glycosidases, can cause misprocessing of glycoproteins, which indirectly impacts the function of β3Gn-T8. Salacinol and isofagomine, both glucosidase inhibitors, and a DNJ-derivative compound, inhibit various glycosidases that are essential for the proper processing and maturation of glycoproteins, consequently inhibiting the function of β3Gn-T8 due to the misprocessing of its substrates.